Brooke Richardson
Family · Montgomery, ALNPI 1043742489
Payments from drug & device makers
Across 209 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$945
- Novo Nordisk$489
- Amgen$444
- AstraZeneca$289
- Johnson & Johnson$248
- Bayer$229
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,33498%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 46 | $945 |
| Novo Nordisk | 25 | $489 |
| Amgen(2 entities) | 13 | $444 |
| AstraZeneca | 13 | $289 |
| Johnson & Johnson | 12 | $248 |
| Bayer | 13 | $229 |
| AbbVie | 7 | $223 |
| Amarin Pharma, Inc. | 11 | $209 |
| Astellas Pharma US Inc | 8 | $202 |
| Sumitomo Pharma America, Inc. | 9 | $148 |
| Lilly USA, LLC | 8 | $129 |
| Ardelyx, Inc. | 5 | $120 |
| Boehringer Ingelheim | 6 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $98 |
| Pfizer | 5 | $91 |
| Merck | 2 | $86 |
| Exact Sciences | 5 | $84 |
| Sanofi-aventis U.S. LLC | 3 | $61 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Dexcom, Inc. | 2 | $34 |
| Novartis | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,429 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $150,553 |
| LinzessLinaclotide | 80 | $81,197 |
| JardianceEmpagliflozin | 50 | $73,904 |
| MounjaroTirzepatide | 60 | $67,767 |
| TrulicityDulaglutide | 42 | $54,228 |
| EliquisApixaban | 56 | $53,640 |
| FarxigaDapagliflozin Propanediol | 33 | $46,072 |
| MyrbetriqMirabegron | 38 | $38,909 |
| RybelsusSemaglutide | 12 | $30,382 |
| GemtesaVibegron | 22 | $29,930 |
| JanuviaSitagliptin Phosphate | 29 | $29,868 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $22,482 |
| VascepaIcosapent Ethyl | 24 | $19,926 |
| TradjentaLinagliptin | 27 | $19,163 |
| XareltoRivaroxaban | 14 | $13,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $489 | $180,935142 claims |
| Lilly USA, LLCMounjaro, Trulicity | $129 | $121,995102 claims |
| Boehringer IngelheimJardiance, Tradjenta | $106 | $93,06777 claims |
| AbbVieLinzess | $223 | $81,19780 claims |
| PfizerEliquis | $91 | $53,64056 claims |
| MerckJanuvia, Janumet Xr | $86 | $52,34949 claims |
| AstraZenecaFarxiga | $289 | $46,07233 claims |
| Astellas Pharma US IncMyrbetriq | $202 | $38,90938 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $148 | $29,93022 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $945 | $15,01024 claims |
| Johnson & JohnsonXarelto | $248 | $13,71014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Montgomery
- Leigh LunaMontgomery$69K
- Brandy YoungMontgomery$27K
- Angela RaybornMontgomery$22K
- Ashley MorrowMontgomery$21K
- Jackie ShumateMontgomery$19K
- Katrina Jones HarrisMontgomery$18K
- Brittney BarberMontgomery$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.